Dermatology Research and Practice / 2021 / Article / Tab 2

Research Article

Intralesional Bleomycin for the Treatment of Resistant Palmoplantar and Periungual Warts

Table 2

Literature review (from the year 2005 to August 2020).

AuthorsIntervention (study design)ResultsFollow-up duration

Our studyIL bleomycin only (retrospective case series)CC (89.47%), RR (15.78%)3 months
Barkat et al. [12]IL bleomycin vs. placebo (RCT)Bleomycin = dermoscopic clearance (69.3%); CC (88.5%), CC of placebo (0%)3 months
Pasquali et al. [13]IL bleomycin + electropolation vs. IL bleomycin only (prospective case series)CC of IL bleomycin + electroporation (78%), bleomycin only (16%)3 months
Dhar et al. [8]IL bleomycin vs. cryotherapy (RCT)CC of bleomycin (94.9%); cryotherapy (76.5%); RR (13%)8 weeks
Adalatkhah et al. [14]IL bleomycin vs. cryotherapy (RCT)CC of bleomycin (86%), cryotherapy (68%)6 weeks
Al-Naggar et al. [15]IL bleomycin vs. microneedling assisted topical bleomycin spray (RCT)CC of IL bleomycin (70%), CC of microneedling-assisted topical spray (83.3%)6 months
Soni et al. [9]IL bleomycin vs. placebo (RCT)CC of IL bleomycin (96.47%) vs. placebo (11.11%)12 months
Salk and Douglas [16]IL bleomycin only (prospective study)CC (87%), RR (19.35%)6 months
Alghamdi and Khurram [17]Translesional multipuncture technique with 0.1 U/ml concentration for periungual warts (prospective study)CC (86.6%), RR (13.33%)6 months
Alghamdi and Khurram [11]Translesional multipuncture technique with 0.1 U/ml concentration for plantar warts (prospective study)CC (74%), no response (13%), RR: 9.5%3 months
Aziz-Jalali et al. [5]IL bleomycin (retrospective study)CC (73%), RR (23%)6 months

RCT: randomized controlled trial, CC: clinical clearance, RR: recurrence rate.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.